connect credit-where-credits-due 
Worldwide Clinical Trials
FEBRUARY 22, 2023
Katie Nichols: What is your connection to rare disease communities? I also recently started a weekly podcast called Two Disabled Dudes where we focus on living life beyond your circumstances. Patients are living longer due to innovation, and we need to be sure we are meeting them where they are. So, I decided to pivot.
pharmaphorum
APRIL 12, 2022
The healthcare landscape has shifted dramatically due to the pandemic. What was once usual practice for pharma – connecting with stakeholders through face-to-face interactions – has pivoted into the need to make meaningful relationships digitally.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 17, 2021
This is largely credited to strong vaccination campaigns spearheaded by the government and health officials in the country. This is largely due to increased awareness and the growing incidence of neurological conditions like depression, chronic pain and neurodegenerative disorders. billion and is expected to grow to $8.8
The Pharma Data
DECEMBER 12, 2020
The combined company is expected to maintain a strong, investment-grade credit rating, and the acquisition supports AstraZeneca’s progressive dividend policy. AstraZeneca remains committed to maintaining a strong investment-grade credit rating.
The Pharma Data
OCTOBER 29, 2020
We are also focused on minimizing potential interactions that could contribute to the spread of the virus and put additional strain on healthcare systems through the use of innovative virtual means where possible. Remaining cohorts of the study, which had previously been paused due to COVID-19, have been restarted.
The Pharma Data
NOVEMBER 30, 2020
are serving as AeroCare’s legal counsel in connection with the transaction. In connection with the acquisitions of AeroCare and New England Home Medical Equipment, the Company is increasing financial guidance for fiscal year 2021 for net revenue from a range of $1.30 Morgan Stanley & Co. billion to $1.40 billion to a range of $2.05
The Pharma Data
AUGUST 6, 2020
Revenues remained consistent on a pro forma basis, as sales were estimated to be negatively impacted by approximately $600 million due mainly to COVID-19 related channel inventory work downs from the first quarter, as well as lower demand resulting from reduced new patient starts and fewer patient visits to physicians in the pandemic.
Expert insights. Personalized for you.
130 
Let's personalize your content